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Stenotrophomonas maltophilia is an emerging multidrug-resistant opportunistic pathogen with an increasing incidence of
nosocomial and community-acquired infection cases, mainly in immunocompromised individuals. Oral cavity infections are rare.
To learn more about this infection, a case of oral cavity infection caused by S. maltophilia in an immunosuppressed patient under
ventilatory therapy has been presented. (e patient presented with multiple nonpainful erosive lesions of the tongue, palate, and
oral mucosa. A smear of the oral lesions was performed that revealed the presence of S. maltophilia and Candida albicans, and the
patient was treated with fluconazole and sulfamethoxazole associated with trimethoprim in accordance with the antimicrobial
susceptibility testing. After 14 days of antibiotic therapy, there were almost no signs of the previous lesions.
1. Introduction
Stenotrophomonas maltophilia is an emerging multidrug-
resistant opportunistic pathogen [1]. It is a Gram-negative
obligate aerobe bacterium found in aqueous habitats. In
clinical practice, it is usually found in hospital suction
tubing, ventilator inspiratory or expiratory circuits, central
venous catheters, dental suction system hoses, hemodialysis
water, and dialysate of renal units [1, 2]. Although not highly
virulent, the increasing incidence of nosocomial and com-
munity-acquired S. maltophilia infections is of particular
concern for immunocompromised individuals, as this
bacterial pathogen is associated with high morbidity and
mortality [1–6]. Risk factors for Stenotrophomonas malto-
philia infection include underlying malignancy [7], the
presence of indwelling devices [7], chronic respiratory
disease, immunocompromised host [7], prior use of anti-
biotics [8], and long-term hospitalization or ICU stay [6, 9].
Although infections by Stenotrophomonas maltophilia can
occur in a lot of different organs and tissues, this agent is
commonly found in respiratory tract infections like pneu-
monia or acute exacerbations of chronic obstructive
pulmonary disease. Less frequent infections can occur in soft
tissue and skin, bloodstream, urinary tract, surgical-site
related infections, endocarditis, meningitis, intra-abdominal
infections, and endophthalmitis [10–25]. Oral cavity in-
fections are not described.
2. Case Report
A 78-year-old female was hospitalized at an intermediate
care unit due to a cardiorespiratory decompensation. (e
patient had history of high blood pressure associated with
hypertensive cardiopathy and cardiac insufficiency, diabetes
mellitus type 2, chronic kidney disease under dialysis, and
chronic obstructive pulmonary disease with respiratory
insufficiency.
After 11 days of noninvasive ventilatory support and due
to the sudden onset of oral lesions, she was referred to the
Stomatology Department for observation. At this moment,
the patient was on day 10 of antibiotic therapy with
piperacillin-tazobactam because of a pneumonia caused by
Streptococcus pneumoniae and under oral fluconazole and
topical nystatin since the appearance of the oral lesions,
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without any improvement.
Upon clinical examination, there were multiple erosive
lesions of the tongue, palate, and oral mucosa (Figure 1).(e
tongue lesions were covered by a cream color membrane
that was detachable. None of the lesions were painful.
We decided to do a biopsy of the ulcers and a smear of
the mouth with fungal and bacterial exam and maintain the
antibiotic and antifungal therapy.
(e histopathological examwas described as an “unspecific
ulcer.”(e bacterial exam of the smear revealed an infection by
a multidrug-resistant Stenotrophomonas maltophilia only
sensitive to cotrimoxazol (sulfamethoxazole+ trimethoprim), and
the fungal exam revealed the presence of Candida albicans.
Following the antimicrobial susceptibility testing and
after discussing with the Intermediate Care Unit team, the
antibiotic was changed while maintaining the antifungal
therapy.
After 6 days, there were clear signs of improvement
(Figure 2). At the day of the discharge, after 14 days of
directed antibiotic therapy, there were almost no signs of the
previous lesions (Figure 3).
3. Discussion and Conclusion
(is case report involves a 78-year-old female with an oral
infection caused by Stenotrophomonas maltophilia and
(a) (b)
Figure 1: Tongue (a) and palatal (b) lesions when first observed.
Figure 2: Tongue lesions 6 days after beginning directed antibiotic therapy.
(a) (b)
Figure 3: Tongue (a) and palate (b) at the discharge day after 14 days of directed antibiotic therapy.
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Candida albicans. Diagnosis was based on the oral smear
with bacterial and fungal exam. Biopsy and histopathological
exam were not useful in this case. Confirmation of the in-
fection and the antimicrobial susceptibility test allowed us to
change the antibiotic accordingly. (e patient had a good
oral evolution after beginning directed antibiotic therapy
with no prejudice to the improvement of her systemic
condition. Due to the fact that Stenotrophomonas malto-
philia is a multidrug-resistant opportunistic pathogen with
an increasing incidence in immunocompromised individ-
uals and since the patient was already under antibiotic
therapy, the identification of the agent and its antibiotic
susceptibility was a key factor to the positive outcome. (is
case goes accordingly to literature where it is stated that
cotrimoxazol is the most effective antibiotic against Steno-
trophomonas maltophilia [4, 5, 26–29]. However, there has
been an increase in antibiotic resistance observed in
S. maltophilia isolates worldwide, and the lag in develop-
ment of new antimicrobials emphasizes the need to develop
novel therapeutics [27–31].
In conclusion, the incidence of Stenotrophomonas
maltophilia-related infections is increasing and we have to
be aware of the possibility of oral infections caused by this
agent mainly in immunocompromised patients under
ventilatory support. (is case also shows that the oral smear,
which is not usually used in oral cavity due to its rich normal
flora, can be an important tool on the diagnosis and
treatment of these conditions.
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